ArticleEuropean journal of pediatrics2025
Impact of COVID-19 pandemic policies on ADHD medication prescriptions among children and adolescents in Portugal.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal study on the seasonal variation in methylphenidate consumption in the South African private healthcare sector.Exploratory research in clinical and social pharmacy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to analyse the prescription of medication for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, by age group and gender, before and during the COVID-19 pandemic, as well as the impact of government policies during this period. This study was a retrospective cohort analysis using data from the Portuguese national prescription database and included all children and adolescents aged 5-19 years. We conducted an interrupted time series analysis, modelled using a seasonal autoregressive integrated moving average (SARIMA) approach, to evaluate the impact on prescription medications while considering two intervention points resulting from government policies: March 2020, marking the start of strict anti-pandemic measures, and May 2021, marking the beginning of their easing. Following the start of strict anti-pandemic measures, from March 2020 to May 2021, a 9% lower prescription rate than expected was observed, while from June 2021 to December 2023, the prescription rate was greater than expected (+ 32%, with a peak of + 41% in children 5-9 years old) and more pronounced in girls.
conclusionsThese findings highlight the complex impact of the pandemic on different age groups and between genders on the prescription of ADHD medicines. WHAT IS KNOWN: • ADHD medications are considered effective and have been increasingly prescribed to children and adolescents in recent years. WHAT IS NEW: • Following the COVID-19 pandemic, the increase in ADHD medication prescriptions exceeded expected trends. • Stratification by age group and gender revealed gender differences, with a more pronounced rise in prescriptions observed among girls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.